Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

about

Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.

P2860

Q47828100-3313A05A-938F-46DE-BC29-82B19B876B72

P2860

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

Item

http://www.wikidata.org/entity/Q39039083

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

@en

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

@nl

type

Item

label

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

@en

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

@nl

prefLabel

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

@en

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

@nl

P1476

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

@en

P2093

A Berrocal

http://www.w3.org/2001/XMLSchema#string

A G Castano

http://www.w3.org/2001/XMLSchema#string

A Soria

http://www.w3.org/2001/XMLSchema#string

C Aguado

http://www.w3.org/2001/XMLSchema#string

C Montagut

http://www.w3.org/2001/XMLSchema#string

D Rodriguez

http://www.w3.org/2001/XMLSchema#string

E Espinosa

http://www.w3.org/2001/XMLSchema#string

E Muñoz

http://www.w3.org/2001/XMLSchema#string

F Barron

http://www.w3.org/2001/XMLSchema#string

J F Rodríguez

http://www.w3.org/2001/XMLSchema#string

P2860

Nivolumab plus ipilimumab in advanced melanoma.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

P2888

s12094-016-1602-1

P304

761-768

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-016-1602-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28054320

http://www.w3.org/2001/XMLSchema#string

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

about

P2860

P2860

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698